Thus, in the event of a cardiac dysfunction, inhibiting CB1 would be cardioprotective against ischemia-reperfusion injury, heart failure, arrhythmia, or cardiomyopathies, while activating CB2 would be cardioprotective. The gene discussed is CNR2; the disease is cardiac arrhythmia.